The status quo of targeted therapy in bladder cancer / 医学研究生学报

ABSTRACT

Bladder cancer is the most common malignant tumor of the urinary system. Prognosis of advanced or metastatic bladder urothelial carcinoma is usually poor. More than half of the patients cannot receive standard, first-line cisplatin-based chemotherapy due to renal dysfunction, cachexia or other complications. As targeted drugs shine in cancer treatment, targeted therapy for bladder cancer has also entered clinical research. This article reviews the targeted therapies include human epithelial growth factor family, vascular endothelial growth factor and receptor, fibroblast growth factor receptor, phosphoinositide 3-kinase-AKT-mammalian target of rapamycin.